Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children.
Bacteria
Dysbiosis
Inflammatory Bowel Disease
Microbiome
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
05
09
2018
revised:
02
04
2019
accepted:
05
04
2019
pubmed:
23
4
2019
medline:
19
8
2021
entrez:
23
4
2019
Statut:
ppublish
Résumé
Fecal microbiota transplantation (FMT) is commonly used to treat Clostridium difficile infection (CDI). CDI is an increasing cause of diarrheal illness in pediatric patients, but the effects of FMT have not been well studied in children. We performed a multi-center retrospective cohort study of pediatric and young adult patients to evaluate the efficacy, safety, and factors associated with a successful FMT for the treatment of CDI. We performed a retrospective study of 372 patients, 11 months to 23 years old, who underwent FMT at 18 pediatric centers, from February 1, 2004, to February 28, 2017; 2-month outcome data were available from 335 patients. Successful FMT was defined as no recurrence of CDI in the 2 months following FMT. We performed stepwise logistic regression to identify factors associated with successful FMT. Of 335 patients who underwent FMT and were followed for 2 months or more, 271 (81%) had a successful outcome following a single FMT and 86.6% had a successful outcome following a first or repeated FMT. Patients who received FMT with fresh donor stool (odds ratio [OR], 2.66; 95% CI, 1.39-5.08), underwent FMT via colonoscopy (OR, 2.41; 95% CI, 1.26-4.61), did not have a feeding tube (OR, 2.08; 95% CI, 1.05-4.11), or had 1 less episode of CDI before FMT (OR, 1.20; 95% CI, 1.04-1.39) had increased odds for successful FMT. Seventeen patients (4.7%) had a severe adverse event during the 3-month follow-up period, including 10 hospitalizations. Based on the findings from a large multi-center retrospective cohort, FMT is effective and safe for the treatment of CDI in children and young adults. Further studies are required to optimize the timing and method of FMT for pediatric patients-factors associated with success differ from those of adult patients.
Sections du résumé
BACKGROUND & AIMS
Fecal microbiota transplantation (FMT) is commonly used to treat Clostridium difficile infection (CDI). CDI is an increasing cause of diarrheal illness in pediatric patients, but the effects of FMT have not been well studied in children. We performed a multi-center retrospective cohort study of pediatric and young adult patients to evaluate the efficacy, safety, and factors associated with a successful FMT for the treatment of CDI.
METHODS
We performed a retrospective study of 372 patients, 11 months to 23 years old, who underwent FMT at 18 pediatric centers, from February 1, 2004, to February 28, 2017; 2-month outcome data were available from 335 patients. Successful FMT was defined as no recurrence of CDI in the 2 months following FMT. We performed stepwise logistic regression to identify factors associated with successful FMT.
RESULTS
Of 335 patients who underwent FMT and were followed for 2 months or more, 271 (81%) had a successful outcome following a single FMT and 86.6% had a successful outcome following a first or repeated FMT. Patients who received FMT with fresh donor stool (odds ratio [OR], 2.66; 95% CI, 1.39-5.08), underwent FMT via colonoscopy (OR, 2.41; 95% CI, 1.26-4.61), did not have a feeding tube (OR, 2.08; 95% CI, 1.05-4.11), or had 1 less episode of CDI before FMT (OR, 1.20; 95% CI, 1.04-1.39) had increased odds for successful FMT. Seventeen patients (4.7%) had a severe adverse event during the 3-month follow-up period, including 10 hospitalizations.
CONCLUSIONS
Based on the findings from a large multi-center retrospective cohort, FMT is effective and safe for the treatment of CDI in children and young adults. Further studies are required to optimize the timing and method of FMT for pediatric patients-factors associated with success differ from those of adult patients.
Identifiants
pubmed: 31009795
pii: S1542-3565(19)30427-6
doi: 10.1016/j.cgh.2019.04.037
pmc: PMC7549313
mid: NIHMS1633139
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
612-619.e1Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000445
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002245
Pays : United States
Organisme : NIAID NIH HHS
ID : L30 AI140315
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK058404
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK034854
Pays : United States
Informations de copyright
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
PLoS One. 2017 Dec 7;12(12):e0189227
pubmed: 29216276
Am J Gastroenterol. 2014 Nov;109(11):1728-38
pubmed: 25223575
Nature. 2006 Dec 21;444(7122):1027-31
pubmed: 17183312
Pediatr Infect Dis J. 2014 Apr;33(4):414-6
pubmed: 24168983
Sci Transl Med. 2017 Mar 1;9(379):
pubmed: 28251905
Aliment Pharmacol Ther. 2016 Oct;44(7):715-727
pubmed: 27481036
J Med Microbiol. 2006 Aug;55(Pt 8):1141-1149
pubmed: 16849736
J Clin Gastroenterol. 2011 Nov;45 Suppl:S159-67
pubmed: 21992957
Am J Gastroenterol. 2012 Dec;107(12):1930-1
pubmed: 23211865
Am J Gastroenterol. 2012 Jan;107(1):89-95
pubmed: 22108454
Inflamm Bowel Dis. 2016 Oct;22(10):2402-9
pubmed: 27580384
Aliment Pharmacol Ther. 2017 Apr;45(7):899-908
pubmed: 28220514
Gut Microbes. 2013 Mar-Apr;4(2):125-35
pubmed: 23333862
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Pediatrics. 2010 Jul;126(1):e239-42
pubmed: 20547640
Clin Infect Dis. 2013 May;56(10):1401-6
pubmed: 23408679
J Pediatr Gastroenterol Nutr. 2019 Jan;68(1):130-143
pubmed: 30540704
Infect Control Hosp Epidemiol. 2015 Apr;36(4):452-60
pubmed: 25626326
Clin Infect Dis. 2015 Jul 1;61(1):136-7
pubmed: 25805303
J Pediatr. 2018 Mar;194:123-127.e1
pubmed: 29198534
JAMA Pediatr. 2018 Jun 4;172(6):e180315
pubmed: 29610864
JAMA. 2016 Jan 12;315(2):142-9
pubmed: 26757463
Am J Infect Control. 2014 Oct;42(10):1028-32
pubmed: 25278388
Aliment Pharmacol Ther. 2017 Sep;46(5):479-493
pubmed: 28707337
Clin Infect Dis. 2011 Nov;53(10):994-1002
pubmed: 22002980
Therap Adv Gastroenterol. 2017 Apr;10(4):373-381
pubmed: 28491142
Infect Control Hosp Epidemiol. 2015 Apr;36(4):438-44
pubmed: 25782899
Infect Control Hosp Epidemiol. 1999 Jan;20(1):43-50
pubmed: 9927265
Clin Gastroenterol Hepatol. 2013 Aug;11(8):1036-8
pubmed: 23669309
Gut Microbes. 2017 Nov 2;8(6):574-588
pubmed: 28723262
J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):23-6
pubmed: 25162365
Ann Intern Med. 1998 Dec 15;129(12):1012-9
pubmed: 9867755
J Pediatric Infect Dis Soc. 2018 Feb 19;7(1):e6-e8
pubmed: 29040661
Front Cardiovasc Med. 2017 Apr 04;4:17
pubmed: 28421185
Nat Rev Endocrinol. 2015 Mar;11(3):182-90
pubmed: 25488483
World J Gastroenterol. 2010 Jan 14;16(2):139-42
pubmed: 20066732
Lancet. 2001 Jan 20;357(9251):189-93
pubmed: 11213096
N Engl J Med. 2015 Feb 26;372(9):825-34
pubmed: 25714160
J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):18-22
pubmed: 25199038